Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDC-1261 in Advanced or Metastatic Prostate Cancer
NCT07567846Phase 2Recruiting
- Sponsor
- Genentech
- Start
- Apr 2026
- Primary completion
- Nov 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of GDC-1261 in prostate cancer (PCa), sponsored by Genentech. Started Apr 2026; status: recruiting.
02
Drugs
GDC-1261
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07567846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07567846.